Details:
SciSparc is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: SCI-110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Yale University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Evero
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 19, 2020